Background ?Effective hepatitis C virus (HCV) treatment may reduce BIIB-024 coronary disease (CVD) risk and improve degrees of CVD biomarkers produced beyond your liver organ (nonhepatic biomarkers). phospholipase A2 [Lp-PLA2]) and hepatic (cholesterol and high-sensitivity C-reactive proteins) CVD and macrophage…